Domain Therapeutics SA has nominated PAR2 antagonist DT-9046 as a drug candidate with potential to treat various inflammatory diseases, including atopic dermatitis, inflammatory bowel disease and ...
Domain Therapeutics SA has disclosed proteinase-activated receptor 2 (PAR2; F2RL1) antagonists reported to be useful for the treatment of allergy, autoimmune and metabolic diseases, cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results